Fortunately, in recent years, many new drugs have been identified in the management of diabetic patients, and although both SGLT2 inhibitors and DPP-4 inhibitors seem to reduce EAT [115,116], it is unclear whether SGLT2 inhibitors are superior to DPP-4 inhibitors in reducing cardiovascular or cardiometabolic risk factors in patients with early-stage T2DM, without CVD and with a good cardiac function. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.